tetano
Editor, Senior Moderator
Mult Scler Relat Disord
. 2020 Jun 3;44:102250.
doi: 10.1016/j.msard.2020.102250. Online ahead of print.
Covid-19 in a Patient With Multiple Sclerosis Treated With Natalizumab: May the Blockade of Integrins Have a Protective Role?
Clara Aguirre[SUP] 1 [/SUP], Virginia Meca-Lallana[SUP] 2 [/SUP], Ana Barrios-Blandino[SUP] 3 [/SUP], Beatriz Del R?o[SUP] 2 [/SUP], Jose Vivancos[SUP] 4 [/SUP]
Affiliations
Abstract
The disease caused by the new coronavirus SARS-CoV-2 (COVID-19) is currently spread worldwide . Recent data supports SARS-CoV-2 may use integrins to enter human cells. Therefore, anti-integrins therapies might be an alternative against the infection . Natalizumab, approved for Multiple Sclerosis (MS) treatment, acts blocking α4-integrin. We report a MS patient treated with natalizumab who develops COVID-19, with excellent recovery and repeated negative results in 5 consecutive microbiological studies. We postulate this may be due to the blockade of integrins induced by natalizumab.
Keywords: COVID-19; Integrins; Multiple Sclerosis; Natalizumab; SARS-CoV-2.
. 2020 Jun 3;44:102250.
doi: 10.1016/j.msard.2020.102250. Online ahead of print.
Covid-19 in a Patient With Multiple Sclerosis Treated With Natalizumab: May the Blockade of Integrins Have a Protective Role?
Clara Aguirre[SUP] 1 [/SUP], Virginia Meca-Lallana[SUP] 2 [/SUP], Ana Barrios-Blandino[SUP] 3 [/SUP], Beatriz Del R?o[SUP] 2 [/SUP], Jose Vivancos[SUP] 4 [/SUP]
Affiliations
- PMID: 32531754
- DOI: 10.1016/j.msard.2020.102250
Abstract
The disease caused by the new coronavirus SARS-CoV-2 (COVID-19) is currently spread worldwide . Recent data supports SARS-CoV-2 may use integrins to enter human cells. Therefore, anti-integrins therapies might be an alternative against the infection . Natalizumab, approved for Multiple Sclerosis (MS) treatment, acts blocking α4-integrin. We report a MS patient treated with natalizumab who develops COVID-19, with excellent recovery and repeated negative results in 5 consecutive microbiological studies. We postulate this may be due to the blockade of integrins induced by natalizumab.
Keywords: COVID-19; Integrins; Multiple Sclerosis; Natalizumab; SARS-CoV-2.